Results from two large-scale efficacy trials found that injectable cabotegravir (CAB-LA), given every two months, was effective as a form of pre-exposure prophylaxis (PrEP) in preventing HIV in gay men and other men who have sex with men, transgender women who have sex with men, and cisgender women. CAB-LA was developed by ViiV Healthcare and is currently used in HIV treatment. It was approved by the US Food and Drug Administration (FDA) as the first form of injectable PrEP in December 2021. This document focuses on CAB-LA for prevention, outlining what’s known and what’s next for this emerging biomedical HIV prevention strategy.
Advocates’ Primer on Injectable Cabotegravir for PrEP: Trials, Approvals, Rollout and More
COMPASS
Since 2017, the Coalition to Build Momentum, Power, Strategy and Solidarity has broken new ground in transnational HIV activism that’s grounded in rigorous analysis, fearless tactics and collaboration across geographies. We’re winning commitments and changes that will drive epidemic control. Read on to see what the future of AIDS activism looks like.
A Collaborative Approach to HIV Prevention Product Introduction
The HIV prevention product pipeline offers exciting potential to curb HIV incidence. But we know from previous products that translating trial efficacy to population impact is challenging without coordinated effort.
A Global Pandemic Requires an Unprecedented Response
Meeting the ambitious timelines for a COVID-19 vaccine will require an unprecedented multi-faceted, coordinated global response including governments, industry, academic researchers, delivery partners, donors and civil society. This graphic represents the pillars of this landscape — with those organizations mentioned by name representing just a small fraction of the growing number of contributors in the global response to the COVID-19 pandemic.
Excerpted from Five “P”s to Watch.
The Race for a Coronavirus Vaccine
This graphic compares a conventional timeline for vaccine development, anticipating a COVID-19 vaccine available by May 2036, versus the accelerated goal of developing, producing and distributing a vaccine much, much faster. Excerpted from Five “P”s to Watch.
Five “P”s to Watch
HIV vaccine research is making the search for a COVID-19 vaccine faster, safer and more inclusive. The global COVID-19 response evolves by the day—seemingly, even, by the minute—as the world has watched the tally of experimental diagnostics, therapeutics and vaccines tick up into the hundreds. If researchers achieve their goal of making the search for a COVID-19 vaccine the fastest vaccine development effort in history, much of that success will be due to the research knowledge, vaccine platforms, trial networks and community engagement models created through HIV vaccine research.
COVID-19 Vaccine Pipeline Snapshot
A snapshot of the COVID-19 vaccine pipeline. Excerpted from Five “P”s to Watch.
Vaccines Approaches in COVID-19 Vaccine Development
HIV represents one of the most challenging viruses ever encountered. Though an HIV vaccine has yet to be licensed, vaccine science has made enormous strides as it confronts this rapidly-mutating virus. Years of painstaking work to develop vaccines for HIV are now making possible the record-breaking timelines that researchers aspire to for the development of COVID-19 vaccines. Vaccines research has generated more scientific knowledge about immune function and responses than ever existed. And key vaccine platforms are fast-tracking the development and testing of experimental vaccines for COVID-19 today.
Excerpted from Five “P”s to Watch.
A Global Pandemic Requires an Unprecedented Response
Will compressed and overlapping steps get a vaccine faster? The innovations advocated for in Vaccines development that are being employed in the COVID-19 response today include: running certain clinical trials in parallel instead of sequentially; gearing up manufacturing capacity before final study results are in and negotiating public/private commitments in advance to facilitate sustainable access to new vaccines.
Excerpted from Five “P”s to Watch.
The Race for a Coronavirus Vaccine
Will compressed and overlapping steps get a vaccine faster? The innovations advocated for in Vaccines development that are being employed in the COVID-19 response today include: running certain clinical trials in parallel instead of sequentially; gearing up manufacturing capacity before final study results are in and negotiating public/private commitments in advance to facilitate sustainable access to new vaccines.
Excerpted from Five “P”s to Watch.